Metabolic Research

BP-3RA: Triple Receptor Agonist

A research overview of BP-3RA — a single peptide built to activate three metabolic hormone receptors at once — covering its mechanism, the Phase 2 clinical data, safety, and how it compares to earlier single and dual agonists.

Export article
Three glowing receptor proteins connected to a single peptide molecule

What It Is

BP-3RA (research code LY3437943) is a synthetic 39-amino-acid peptide with a fatty-acid side chain that binds albumin, giving it a half-life of about 6 days and allowing once-weekly study schedules. It is the first compound in clinical research designed to activate three receptors with one molecule: GLP-1, GIP, and glucagon.

It is the next step in a progression: BP-1RA activates GLP-1 alone, BP-2RA activates GLP-1 and GIP, and BP-3RA adds the glucagon receptor. That third signal is what sets it apart, because glucagon acts on energy expenditure and liver fat rather than only on appetite.

How It Works

GLP-1 Receptor

GLP-1 activation slows stomach emptying, increases insulin release when blood sugar is high, and acts on brain appetite centers to increase fullness. This is the same pathway studied with BP-1RA.

GIP Receptor

GIP is a second gut hormone that boosts insulin release and appears to improve how fat tissue stores and handles energy. In dual-agonist research it also seems to soften some of the nausea seen with GLP-1 activation alone.

Glucagon Receptor

Glucagon on its own raises blood sugar, which is why it is balanced by the GLP-1 and GIP activity. Its research interest lies elsewhere: it increases energy expenditure, promotes fat breakdown in the liver, and supports fat burning. Preclinical work showed greater weight loss and energy expenditure than dual agonists at matched exposure (Coskun et al., 2022).

BP-3RA is not equally strong at each receptor. It is more potent at GIP than native GIP, and somewhat less potent at GLP-1 and glucagon than the native hormones — a deliberate balance intended to keep blood sugar stable while capturing glucagon's metabolic effects.

What the Science Shows

Phase 2 Obesity Trial

A 48-week randomized, double-blind trial enrolled 338 adults with obesity or overweight plus a related condition (Jastreboff et al., NEJM, 2023). Average weight change at 48 weeks:

Weekly dose studiedMean weight change (48 wk)
Placebo−2.1%
1 mg−8.7%
4 mg−17.1%
8 mg−22.8%
12 mg−24.2%

At the highest dose, 100% of participants lost at least 5% of body weight and about 26% lost 30% or more. Weight had not fully plateaued at 48 weeks.

Type 2 Diabetes

A 36-week Phase 2 trial in 281 adults with type 2 diabetes reported HbA1c reductions of up to about 2.0 percentage points and weight loss of up to about 17%, outperforming the active comparator dulaglutide (Rosenstock et al., Lancet, 2023).

Liver Fat

In a sub-study of participants with fatty liver disease, liver fat fell by roughly 80% at the higher doses after 48 weeks, and most participants reached normal liver-fat levels (Sanyal et al., Nat Med, 2024). This is the effect most clearly linked to the glucagon component.

Ongoing Research

Phase 3 programs are studying obesity, type 2 diabetes, knee osteoarthritis pain, sleep apnea, cardiovascular outcomes, and kidney function.

How It Compares

CompoundReceptorsApprox. weight change in trials
BP-1RAGLP-1~15% at 68 weeks
BP-2RAGLP-1 + GIP~21% at 72 weeks
BP-3RAGLP-1 + GIP + glucagon~24% at 48 weeks (Phase 2)

Cross-trial comparisons are approximate — populations, durations, and designs differ.

Research Protocols Reported in the Literature

The parameters below describe published trial methodology and are not dosing guidance.

  • Schedule: once weekly, subcutaneous.
  • Escalation: trials started at 2 mg (some arms 4 mg) and stepped up every 4 weeks toward 4, 8, or 12 mg; slower escalation reduced stomach side effects.
  • Duration: 36–48 weeks in Phase 2; longer in Phase 3.

Side Effects

  • Gastrointestinal: nausea, diarrhea, vomiting, and constipation were most common — mostly mild to moderate and concentrated during dose increases.
  • Heart rate: a dose-related increase peaking around 24 weeks, then declining.
  • Skin sensitivity: some participants reported unusual skin sensations (dysesthesia).
  • Discontinuation: adverse-event dropouts ranged from about 6% to 16% across doses versus 0% on placebo.

Contraindications and Precautions

Based on the incretin class, research exclusions typically include personal or family history of medullary thyroid cancer or MEN2, history of pancreatitis, pregnancy, and severe gastrointestinal disease. Effects on heart rate warrant monitoring.

Regulatory Status

BP-3RA is investigational and is not approved by the FDA for any use. BioPrime supplies BP-3RA strictly as a reference compound for in-vitro and preclinical laboratory research.

References

  • Jastreboff AM, et al. Triple-hormone-receptor agonist for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526. PubMed
  • Rosenstock J, et al. Efficacy and safety of a triple GIP, GLP-1, and glucagon receptor agonist in type 2 diabetes: a randomised, double-blind, placebo- and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529–544. PubMed
  • Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234–1247. PubMed
  • Sanyal AJ, et al. Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037–2048. PubMed

Disclaimer

This information is not medical advice. Content is provided for educational and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. BioPrime products are sold strictly for in-vitro laboratory research by qualified professionals. Results from any research protocol will vary based on usage, conditions, and methodology.